HROW Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Harrow Inc (HROW) financials, highlighting its revenue breakdown, profitability margins, and competitive positioning. HROW maintains strong gross margins at 79.27% but has a negative Return on Equity (ROE) of -8.42%. The analysis also benchmarks HROW against competitors BHVN and IMTX, noting its significant market capitalization of $1.31 billion.
Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum
Harrow has set a revenue goal of $350 million to $365 million for 2026, driven by an expanding sales force and advancements in its product pipeline. The company is actively pursuing new opportunities and leveraging a growing sales team to achieve its ambitious financial targets. This outlook reflects confidence in its strategic initiatives and market positioning for future growth.
BTIG Maintains Buy on Harrow Health, Inc. (HROW) March 2026
BTIG has reiterated its Buy rating on Harrow Health, Inc. (HROW) on March 18, 2026, ahead of company presentations, indicating continued analyst confidence. The rating was not accompanied by a new price target, and the market reaction was a modest 0.2% increase. This suggests that the announcement confirmed existing expectations rather than introducing new catalysts for investors.
HROW6348836 Bond Coupon Analysis — Rate & Payments
This article provides an analysis of the HROW6348836 bond, issued by Harrow, Inc., detailing its coupon rate and payment schedule. It highlights a current coupon rate of 8.63% and indicates that the next payment is scheduled for September 15, 2026. The piece also suggests that additional coupon data and a full payout schedule are available for further insights into the bond's financial details.
HROW6348836 Bond Risk Analysis
This article provides an analysis of the HROW6348836 bond issued by Harrow, Inc., specifically its 8.625% bond due September 15, 2030. It focuses on offering key metrics for risk assessment, including security level, inflation protection, and issuer rating to help evaluate the bond's reliability. The page also offers access to analyst ratings and data on agents involved.
Discipline and Rules-Based Execution in HROW Response
This article analyzes Harrow Health Inc. (NASDAQ: HROW) with AI-generated signals and various trading strategies. It identifies a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. The analysis provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis.
Harrow prices $50M senior unsecured notes due 2030 at 8.625%
Harrow has priced a private offering of $50 million in senior unsecured notes due in 2030, carrying an interest rate of 8.625%. The offering is expected to close around April 3, 2026, and the proceeds will be used to repurchase a portion of the company's outstanding convertible senior notes.
Harrow prices $50M senior unsecured notes due 2030 at 8.625%
Harrow has priced $50 million in senior unsecured notes due in 2030, carrying an interest rate of 8.625%. The offering is expected to close around April 2, 2026, subject to customary closing conditions. Proceeds from the sale are intended to be used for general corporate purposes.
Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises
Opaleye Management, a 10% owner of Harrow, Inc. (HROW), recently sold nearly 200,000 shares after the company's Q4 2025 earnings miss, though it still retains a significant stake. This sale, combined with Harrow's decision to fund growth with higher-coupon debt instead of equity, signals potential concerns regarding short-term volatility and increased financial risk. Investors are advised to monitor Harrow's future cash flow generation against its new debt obligations and watch for further insider activity.
Harrow Health Expands Senior Notes Offering for Growth
Harrow Health issued an additional $50 million of 8.625% Senior Notes due 2030, integrating them into its existing $250 million note series. The private offering, completed on March 27, 2026, generated approximately $48.7 million in net proceeds, which Harrow Health plans to use for growth initiatives, product development, and strategic opportunities. Despite a "Sell" rating from one analyst and some financial headwinds, the company has a positive earnings-call outlook with strong 2026 revenue and EBITDA guidance.
Harrow Raises $50 Million Via Additional 8.625% Senior Notes Due 2030; Signs Purchase Agreement and Indenture
Harrow (HROW) has raised an additional $50 million through the issuance of 8.625% Senior Notes due 2030, in a private offering to qualified institutional buyers and offshore investors. The net proceeds of approximately $48.7 million will be used for general corporate purposes, including growth initiatives and product development. This issuance expands an existing series of notes, facilitated by a Purchase Agreement with BTIG and a First Supplemental Indenture.
Harrow (NASDAQ: HROW) sells $50M of 8.625% notes due 2030
Harrow, Inc. has issued $50.0 million in additional 8.625% Senior Notes due 2030 through a private offering to qualified institutional buyers and certain non-U.S. investors. The new notes are fungible with existing 2030 notes and share the same terms, except for the issuance date and price. Harrow received approximately $48.7 million in net proceeds, which it plans to utilize for general corporate purposes, including growth initiatives, product development, and strategic business opportunities.
Vanguard disaggregates holdings — Harrow Inc (HROW) reports 0 shares
The Vanguard Group has filed an amended Schedule 13G/A, reporting that it now beneficially owns 0 shares of Harrow Inc (HROW) common stock. This change is due to an internal realignment within Vanguard, effective January 12, 2026, where certain subsidiaries will report beneficial ownership separately. The filing clarifies that this is an administrative disclosure of ownership reporting structure and does not detail prior cash-flow treatment or holdings.
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Harrow, Inc. announced the pricing of a private offering for $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030. These new notes will be treated as part of an existing series from September 2025, maturing on September 15, 2030, with interest payable semi-annually. The company plans to use the net proceeds for general corporate purposes, including accelerating growth, funding product development, and pursuing strategic business opportunities.
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow, Inc. announced an add-on offering of $50.0 million in 8.625% senior unsecured notes due 2030 to support growth initiatives. The proceeds will be used for general corporate purposes, including new product launches, product development, and strategic business development opportunities. The offering is directed towards "qualified institutional buyers" and non-"U.S. persons" and the notes will be treated as part of the same series as previously issued notes.
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow (Nasdaq: HROW) announced its intention to offer an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030. The proceeds from this offering will be used for general corporate purposes, including accelerating growth initiatives like new product launches, funding upcoming product development, and future strategic business development opportunities. These notes will be treated as part of the existing series issued in September 2025.
How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth
Harrow, Inc. recently issued US$50 million in 8.625% senior unsecured notes due 2030, aiming to fund growth initiatives and product development without equity dilution. While this offers financial flexibility, it also moderately increases balance sheet risk and raises the bar for converting products into sustainable earnings to cover higher interest costs. The move supports Harrow's ambitious 2026 revenue guidance but requires careful consideration of the balance between growth and financial leverage.
Harrow Health Prices $50 Million Senior Notes Offering
Harrow Health (HROW) announced the pricing of a $50 million private offering of 8.625% senior unsecured notes due 2030. These new notes will expand Harrow's existing 2030 debt series and the net proceeds are intended for general corporate purposes, including growth initiatives, product development, and strategic business opportunities. Spark, TipRanks' AI Analyst, rates HROW as Neutral, citing high leverage and weak cash flow quality, despite positive recent earnings guidance.
HROW Technical Analysis | Trend, Signals & Chart Patterns | HARROW INC (NASDAQ:HROW)
This article provides a technical analysis of HARROW INC (NASDAQ:HROW), noting its poor overall technical rating of 1 out of 10. Both short-term and long-term trends for HROW are negative, and the stock is trading near the lows of its recent range. Key indicators like the Simple Moving Averages (20 and 50) and the ChartMill Trend Indicators also signal negative trends, suggesting it may not be an attractive investment currently.
Harrow (NASDAQ: HROW) adds $50M to 8.625% 2030 senior notes
Harrow Inc. (NASDAQ: HROW) has announced the pricing of a private offering for an additional $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030. These new notes will be issued under the same indenture as the existing $250 million notes, forming a single series with identical terms, and are expected to close on March 27, 2026. The company plans to utilize the net proceeds for general corporate purposes, including growth initiatives, product development, and strategic business opportunities.
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Harrow, Inc. has priced a private offering of $50.0 million in 8.625% senior unsecured notes due 2030, which are expected to close on March 27, 2026. These new notes will be treated as part of an existing series from September 2025 and will bear interest payable semi-annually. The company plans to use the net proceeds for general corporate purposes, including growth initiatives, product development, and strategic business opportunities.
Harrow Announces $50 Million Add-On Offering of 8.625% Senior Unsecured Notes Due 2030 to Support Growth
Harrow, Inc. is conducting an add-on offering of $50 million in 8.625% senior unsecured notes due 2030. This offering, made privately to qualified institutional buyers, aims to fund general corporate purposes, including growth acceleration, new product development, and strategic business initiatives. The new notes will form a single series with existing notes, bringing the total principal amount to $300 million and supporting Harrow's position in North American ophthalmic disease management.
Harrow announces $50M add-on senior notes offering
Harrow announced a proposed $50 million add-on offering of its 8.625% Senior Notes due 2027. The offering is subject to market and other conditions. The company plans to use the net proceeds for general corporate purposes.
Harrow Health Announces $50 Million Senior Notes Offering
Harrow Health announced a $50 million add-on private offering of 8.625% senior unsecured notes due 2030, intending to use the proceeds for general corporate purposes and growth initiatives, including new product launches and strategic business development. This offering will combine with a previously issued $250 million of identical notes from September 2025. The transaction is subject to market conditions and aims to further scale Harrow's ophthalmic portfolio, despite a "Neutral" rating from TipRanks' AI Analyst, Spark, due to leveraged financials and ongoing net losses.
Harrow launches $50.0M add-on 8.625% senior notes due 2030 for growth initiatives
Harrow (HROW) announced a private offering of $50.0 million in additional 8.625% senior notes due 2030. These new notes will be part of the existing $250.0 million 2030 notes and are intended to fund general corporate purposes, including new product launches, development, and strategic opportunities. The offering is open to qualified institutional buyers and non-U.S. persons offshore.
Harrow (NASDAQ: HROW) plans $50M add-on 8.625% 2030 note issue
Harrow, Inc. (NASDAQ: HROW) announced its intention to offer an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030. These new notes will form a single series with the existing $250 million of 2030 notes issued in September 2025 and will be offered privately to qualified institutional buyers and certain non-U.S. investors. The company plans to use the net proceeds for general corporate purposes, including growth initiatives, product development, and strategic business opportunities.
Harrow Health Inc stock faces valuation scrutiny amid eye care expansion push
Harrow Health Inc is gaining investor attention for its advances in ophthalmic pharmaceuticals and steady revenue growth projections, appealing particularly to DACH investors for diversification in the US healthcare sector. Despite showing upward stock bias on Nasdaq due to new product launches and a focus on specialized vision care, the company faces valuation scrutiny due to high multiples and competitive risks in the biotech space. The article emphasizes the company's strong product pipeline, strategic expansion, and financial trajectory, while also cautioning about potential challenges like supply chain disruptions and regulatory oversight.
HROW: Analyst HC Wainwright & Co. Reiterates 'Buy' with $70 Target
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating for Harrow (HROW) with a maintained price target of $70.00 USD, reflecting continued confidence in the eyecare pharmaceutical company. This update follows several recent analyst actions, including BTIG's 'Buy' rating with a $63 target and Cantor Fitzgerald's 'Overweight' rating with a $91 target. The average one-year price target from 7 analysts for HROW is $68.43, implying a significant upside from its current price.
Harrow's (HROW) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright has reaffirmed a "Buy" rating on Harrow (HROW) with a $70 price target, suggesting a potential 103% upside. Despite a "Moderate Buy" consensus from analysts, the company exhibits financial risks such as a negative trailing P/E and a high debt-to-equity ratio, though it maintains healthy liquidity. Institutional investors hold a significant portion of its shares, and recent trading shows the stock opened at $34.48, with a market cap of $1.28 billion.
Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026
Nomura downgraded Harrow Health, Inc. (HROW) to Neutral on March 18, 2026, citing caution in near-term execution and without publishing a price target. This downgrade resulted in a modest share pullback of -2.49% and represents a shift in market sentiment, contrasting with BTIG's reiterated Buy rating. Investors are advised to monitor upcoming company presentations and financial results to assess the impact of this split in analyst views.
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Harrow, Inc. (Nasdaq: HROW) announced that three scientific abstracts focusing on its ophthalmic products, VEVYE (cyclosporine ophthalmic solution) 0.1% and ILEVRO (nepafenac ophthalmic suspension) 0.3%, have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting. The presentations will cover real-world treatment patterns and clinical outcomes for dry eye disease with VEVYE, its use as an alternative to corticosteroids post-fungal keratoplasty, and the effect of ILEVRO on reducing visual acuity loss after cataract surgery in patients with macular edema. This highlights Harrow's ongoing dedication to advancing evidence-based treatments for various ophthalmic conditions.
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Harrow (Nasdaq: HROW) has announced that three scientific abstracts highlighting its ophthalmic products VEVYE (cyclosporine ophthalmic solution) 0.1% and ILEVRO (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting. The presentations will cover real-world treatment patterns and clinical outcomes for VEVYE in dry eye disease and as an alternative to corticosteroids, as well as a post-hoc analysis of ILEVRO's effect on reducing visual acuity loss after cataract surgery in patients with macular edema. This acceptance underscores Harrow's dedication to advancing evidence-based treatment options for ophthalmic conditions.
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research
BTIG Research has reaffirmed a "buy" rating for Harrow (NASDAQ:HROW) and set a price target of $63.00, suggesting a potential upside of 77.04%. Despite being traded below analyst targets and its moving averages, the company holds a "Moderate Buy" consensus rating among analysts with an average target of $71.14. Harrow, a biopharmaceutical company specializing in ophthalmic therapeutics, has a market cap of $1.32 billion and 72.76% institutional ownership.
Penn Capital Management Company LLC Makes New Investment in Harrow, Inc. $HROW
Penn Capital Management Company LLC has purchased a new stake in Harrow, Inc. (NASDAQ:HROW), acquiring 325,478 shares valued at approximately $15.72 million. This investment means Penn Capital Management now owns 0.88% of Harrow, contributing to the 72.76% institutional ownership of the company's stock. Analyst opinions are mixed, with a consensus "Moderate Buy" rating and an average price target of $71.14, though some firms like Zacks have downgraded the stock to "strong sell."
Eye drug studies on dry eye and cataract surgery headed to DC stage
Harrow (Nasdaq: HROW) announced that three scientific abstracts featuring its commercial products VEVYE 0.1% and ILEVRO 0.3% have been accepted for presentation at the ASCRS 2026 Annual Meeting. These studies cover dry eye disease and outcomes following cataract surgery. The presentations are scheduled for April 11-12, 2026, in Washington, D.C., and will provide detailed data during the sessions.
307,337 Shares in Harrow, Inc. $HROW Bought by Luxor Capital Group LP
Luxor Capital Group LP has acquired 307,337 shares of Harrow, Inc. (NASDAQ:HROW) valued at approximately $14.8 million during the third quarter, making it their 20th-largest holding and representing 0.83% ownership. Other institutional investors like The Manufacturers Life Insurance Company and Alliancebernstein L.P. also increased their stakes. Harrow currently trades around $34.91, and analysts have a "Moderate Buy" consensus rating with an average target price of $71.14.
Braidwell LP Decreases Stock Position in Harrow, Inc. $HROW
Braidwell LP significantly reduced its stake in Harrow, Inc. by 60.7% in the third quarter, while other institutional investors like New York State Common Retirement Fund increased their positions. Harrow's stock opened lower, trading below its consensus price target with a negative P/E ratio and high debt-to-equity. Analysts have issued varied ratings, resulting in a "Moderate Buy" consensus.
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Harrow, Inc. (NASDAQ: HROW) has received a consensus "Moderate Buy" recommendation from ten brokerages, with an average 12-month price target of $71.14. Despite favorable analyst ratings, the company's shares opened lower, with a negative PE ratio and a high debt-to-equity ratio indicating financial challenges. Institutional investors hold a significant stake, with several firms acquiring new or larger positions in the company recently.
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress
Harrow (HROW) has shown strong revenue growth and is advancing its TRIESENCE program into Phase 3 trials, leading to a "Most Popular Narrative" valuing the stock at $70.63, nearly double its current price. Despite these positive developments, the stock's short-term momentum is fading, and its P/S ratio of 4.9x is higher than the US pharmaceuticals average, suggesting a mixed outlook for valuation. Investors are encouraged to assess the balance between potential upside from aggressive growth and profitability against existing valuation risks and market sentiment.
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress
Harrow (HROW) has seen strong revenue growth in Q4 and 2025 and is advancing its TRIESENCE program into a Phase 3 trial. Despite recent share price gains, the company's valuation remains a point of discussion, with some narratives suggesting it is significantly undervalued at $70.63 per share compared to its last close of $35.56. However, its current P/S ratio of 4.9x is above the US pharmaceuticals average, indicating a more cautious market view despite significant growth potential in the ophthalmic market.
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3
Harrow, Inc. reported strong Q4 and full-year 2025 revenue and provided ambitious 2026 guidance, while also advancing its TRIESENCE drug to a Phase 3 trial for ocular inflammation. Despite these positive developments, the stock is down 6.5%, indicating investor focus on the risks associated with TRIESENCE's trial outcomes and the company's dependency on a few key drugs. Success in the Phase 3 trial could significantly broaden TRIESENCE's market and de-risk Harrow's investment profile.
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported
Daniel Kaufman has reported beneficial ownership of 1,878,000 shares of Harrow, Inc. (HROW) common stock, which represents a 5.04% stake. This disclosure was made in a Schedule 13G SEC filing on March 10, 2026, indicating passive investment with sole voting and dispositive power over the shares. The filing does not suggest any immediate plans for buying or selling additional shares.
HROW Stock Price, Quote & Chart | HARROW INC (NASDAQ:HROW)
HARROW INC (NASDAQ:HROW) currently trades at $34.1, down 4.11% today. The stock has shown significant long-term growth, increasing by 405.19% over five years, but has declined 27.63% in the past month. Analysts have an average price target of $72.13, suggesting a potential 111.52% increase, and anticipate strong EPS and revenue growth for the coming year.
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3
Harrow, Inc. (HROW) experienced a 6.5% stock drop despite reporting strong Q4 2025 sales and full-year revenue, issuing ambitious 2026 guidance, and receiving FDA clearance for a Phase 3 trial of TRIESENCE. The market's reaction suggests investor caution regarding the company's reliance on a few key drugs and the potential risks associated with the TRIESENCE trial, even while analysts project significant long-term growth and a high fair value for the stock. The outcome of the TRIESENCE trial is now a central short-term catalyst that could significantly impact Harrow's investment narrative.
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3
Harrow (HROW) experienced a 6.5% stock drop despite strong Q4 2025 sales, raising 2026 revenue guidance, and advancing its TRIESENCE drug to Phase 3 trials for ocular inflammation. The company's investment narrative is now heavily reliant on successful TRIESENCE trial outcomes, as positive data could expand its market share for cataract surgery use. However, investors face risks related to trial failure or delays, as well as the company's dependency on a few key drugs.
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus
Harrow Health Inc. presented at the Leerink Global Healthcare Conference 2026, where CEO Mark Baum detailed the company's strong financial performance with a five-year revenue CAGR over 41% and adjusted EBITDA CAGR over 61%. The company plans strategic expansions for its VEVYE and IHEEZO products, advancements for TRIESENCE, and the development of G-MELT, despite a recent stock decline. Harrow Health emphasized its commitment to growth, commercial execution, and expanding its ophthalmic product portfolio.
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches
Harrow, Inc. (HROW) is experiencing strong five-year growth with record revenues and EBITDA. This growth is attributed to its diverse ophthalmic portfolio, which includes key products like VEVYE, IHEEZO, and TRIESENCE that are expanding market share. The company's future growth is further supported by biosimilars and a robust pipeline of assets.
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions
Harrow Inc. (HROW) reported record financial results for Q4 and full-year 2025, with consolidated revenue reaching $89.1 million in Q4 and $272 million for the full year, representing significant year-over-year growth. The company is strategically expanding its sales force for key ophthalmic products like VEVYE and TRIESENCE and is advancing its pipeline with promising new products. Despite anticipating a softer first half of 2026 due to inventory drawdowns and increased SG&A expenses, Harrow Inc. provided positive 2026 revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million.
Harrow, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HROW)
This article provides access to the slide deck published by Harrow, Inc. in conjunction with their Q4 2025 earnings call. The presentation was released on March 6, 2026. The content is primarily a gateway to the earnings call presentation material.
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors
Harrow (HROW) has experienced a significant stock slide recently, but analyses suggest it may be undervalued. A Discounted Cash Flow (DCF) model indicates an 89.0% discount on its intrinsic value, while the P/S ratio, adjusted for growth and risk, also points to the stock trading below its fair value. These findings suggest a potential opportunity for investors despite the recent volatility in the share price.
